Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent FOLFIRINOX Plus HIFU for Pancreatic Cancer
NCT05262452Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in pancreatic cancer (PC), sponsored by Seoul National University Hospital. Primary endpoints: Tumor Response Rate at 6 months and Percentage of subjects that were subject to surgical resection at 6 months. Status: unknown.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05262452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262452.